A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients

Trial Profile

A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2018

At a glance

  • Drugs Amifampridine (Primary)
  • Indications Myasthenia gravis
  • Focus Registrational; Therapeutic Use
  • Sponsors Catalyst Pharmaceutical
  • Most Recent Events

    • 04 Jan 2018 Planned initiation date changed from 1 Dec 2017 to 1 Feb 2018.
    • 02 Oct 2017 Status changed from planning to not yet recruiting.
    • 30 Aug 2017 According to a Catalyst Pharmaceuticals media release, FDA grants Special Protocol Assessment (SPA) agreement for this trial and looking forward to dosing the first patients in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top